AbstractFirst-line multiple myeloma treatment has evolved from melphalan–prednisone to quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results